company background image
AMG logo

Amgen XTRA:AMG Stock Report

Last Price

€261.80

Market Cap

€139.0b

7D

4.5%

1Y

19.4%

Updated

26 Mar, 2024

Data

Company Financials +

Amgen Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Amgen
Historical stock prices
Current Share PriceUS$261.80
52 Week HighUS$306.00
52 Week LowUS$196.60
Beta0.58
1 Month Change-2.68%
3 Month Change1.87%
1 Year Change19.41%
3 Year Change22.54%
5 Year Change52.32%
Change since IPO352.39%

Recent News & Updates

Recent updates

Shareholder Returns

AMGDE BiotechsDE Market
7D4.5%2.1%1.9%
1Y19.4%37.0%7.3%

Return vs Industry: AMG underperformed the German Biotechs industry which returned 35.8% over the past year.

Return vs Market: AMG exceeded the German Market which returned 6.4% over the past year.

Price Volatility

Is AMG's price volatile compared to industry and market?
AMG volatility
AMG Average Weekly Movement3.4%
Biotechs Industry Average Movement5.8%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: AMG has not had significant price volatility in the past 3 months.

Volatility Over Time: AMG's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198026,700Bob Bradwayhttps://www.amgen.com

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI.

Amgen Inc. Fundamentals Summary

How do Amgen's earnings and revenue compare to its market cap?
AMG fundamental statistics
Market cap€138.95b
Earnings (TTM)€6.20b
Revenue (TTM)€26.03b

22.5x

P/E Ratio

5.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AMG income statement (TTM)
RevenueUS$28.19b
Cost of RevenueUS$8.42b
Gross ProfitUS$19.78b
Other ExpensesUS$13.06b
EarningsUS$6.72b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)12.53
Gross Margin70.15%
Net Profit Margin23.83%
Debt/Equity Ratio1,036.8%

How did AMG perform over the long term?

See historical performance and comparison

Dividends

3.2%

Current Dividend Yield

68%

Payout Ratio

Does AMG pay a reliable dividends?

See AMG dividend history and benchmarks
When do you need to buy AMG by to receive an upcoming dividend?
Amgen dividend dates
Ex Dividend DateMay 16 2024
Dividend Pay DateJun 07 2024
Days until Ex dividend50 days
Days until Dividend pay date72 days

Does AMG pay a reliable dividends?

See AMG dividend history and benchmarks
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.